培非格司亭生物类似药（Biocon）(Pegfilgrastim-Jmdb) - 药物靶点：CSF-3R_在研适应症：中性粒细胞减少，粒细胞减少性发热，化疗引起的发热性中性粒细胞减少症_专利_临床

概要

基本信息

药物类型

生物类似药、集落刺激因子

别名

Fulphila、PEG G CSF、pegfilgrastim

+ [3]

靶点

CSF-3R

作用方式

激动剂

作用机制

CSF-3R激动剂(巨噬细胞集落刺激因子3受体激动剂)

治疗领域

血液及淋巴系统疾病

在研适应症

中性粒细胞减少粒细胞减少性发热化疗引起的发热性中性粒细胞减少症

非在研适应症-

原研机构

Biocon Ltd.

在研机构

Biocon Biologics Ireland Ltd.Mylan Pharmaceuticals, Inc.

Biocon Ltd.

+ [2]

非在研机构

Mylan NV

权益机构

Biocon Ltd.

Mylan NV

最高研发阶段批准上市

首次获批日期

美国 (2018-06-04),

化疗引起的发热性中性粒细胞减少症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 4190

当前序列信息引自: *****

关联

22

项与培非格司亭生物类似药（Biocon）相关的临床试验

JPRN-jRCT2071210138

/ Completed临床1期IIT

To compare the Pharmacokinetics (PK) / Pharmacodynamics(PD)of a single subcutaneous (sc) injection (3.6 mg) of MYL-1401H and G-Lasta in Japanese healthy adult volunteers

开始日期2022-03-17

申办/合作机构-

NCT05573386

/ Unknown statusN/AIIT

A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim

The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and pegfilgrastim. The main question it aims to answer is:
• Will participants have a similar cellular content when comparing a 4-day filgrastim treatment to a one-day pegfilgrastim treatment?
Participants will have the following intervention administered:
* 130mL of blood will be drawn on the first visit after consent and in followup visits after administering treatment (4 days for filgrastim, 7 days for pegfilgrastim)
* Half of all participants will receive filgrastim first, followed by pegfilgrastim 8 weeks after filgrastim treatment concludes. The other half will receive the treatments in reverse order
Researchers will compare the quality and quantity of cell content after each treatment administration as well as comparing differences in data dependent on which order treatment was given.

开始日期2021-08-09

申办/合作机构

Andrews Research & Education Foundation, Inc.

IRCT20180119038433N3

/ Suspended临床3期IIT

Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy, a randomization clinical trial.

开始日期2020-10-22

申办/合作机构

Semnan University

100 项与培非格司亭生物类似药（Biocon）相关的临床结果

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的转化医学

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的专利（医药）

登录后查看更多信息

13

项与培非格司亭生物类似药（Biocon）相关的文献（医药）

2023-08-01·Clinical pharmacology in drug development

Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor

Article

作者: Ishizawa, Keisuke ; Ishida, Tatsuhiro ; Taro, Shimizu ; Nakamura, Shingen ; Okada, Naoto ; Ando, Hidenori ; Goda, Mitsuhiro ; Kitahara, Takashi ; Abe, Masahiro

Abstract:

Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half‐life and efficacy. We previously reported that the PEGylated granulocyte colony‐stimulating factor (PEG‐G‐CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti‐PEG antibody titers and the clinical impact of PEG‐G‐CSF in 19 hematological patients. A gradual decrease of anti‐PEG antibody titers from baseline was observed after PEG‐G‐CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG‐G‐CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut‐off values of pretreated anti‐PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti‐PEG antibody titers above this cut‐off value (P = .033). An enzyme‐linked immunosorbent assay revealed that some anti‐PEG antibodies in patients with anti‐PEG antibody titers above the cut‐off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti‐PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti‐PEG antibodies and the development of adverse events after PEG‐G‐CSF administration.

2023-02-01·Journal of managed care & specialty pharmacy

Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study

Article

作者: Brown, Joshua D ; Heldermon, Coy D ; Park, Haesuk ; Vouri, Scott M ; Wang, Ching-Yu

BACKGROUND: Real-world evidence on the comparative effectiveness of pegfilgrastim biosimilars compared with the originator product is limited. OBJECTIVE: To compare the risk of febrile neutropenia (FN) among users of pegfilgrastim biosimilars (pegfilgrastim-jmdb and pegfilgrastim-cbqv) and the originator product. METHODS: A retrospective cohort study was conducted using 2019 IBM MarketScan databases to assess comparative effectiveness of pegfilgrastim originator and biosimilars for prevention of FN among patients receiving myelosuppressive chemotherapy. Patients with cancer, including breast, lung, colorectal, esophageal and gastric, pancreatic, prostate, ovarian, and non-Hodgkin lymphomas, initiating myelosuppressive chemotherapy courses were selected. We further selected patients who used pegfilgrastim originator and biosimilars within 3 days of chemotherapy completion. FN-associated hospitalizations were measured by International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes. After 1:1 propensity score matching, we used equivalence (with a margin of 6%) hypothesis tests to compare FN-related hospitalization risk in the first cycle and across all cycles between biosimilars and originator users. RESULTS: A total of 2,045 patients were included, of which 445 (21.8%) used pegfilgrastim-jmdb, 636 (31.1%) used pegfilgrastim-cbqv, and 964 (47.1%) used pegfilgrastim originator. After matching, 13 out of 445 originator users and 17 out of 445 pegfilgrastim-jmdb users developed FN after the first chemotherapy cycle (risk difference was 0.9%; P < 0.001 for equivalence test indicating statistical equivalence). After matching, 14 out of 633 originator users and 16 out of 633 pegfilgrastim-cbqv users developed FN (risk difference was 0.32%; P < 0.001 for equivalence test indicating statistical equivalence). Results across all cycles (including the first cycle) were consistent with that in the first cycle. CONCLUSIONS: In this real-world study of patients with cancer receiving myelosuppressive chemotherapy, there was no difference in FN risk between patients receiving pegfilgrastim originator and biosimilars in the first cycle and across all cycles. These results add further to the current evidence on pegfilgrastim biosimilars and support wider adoption of pegfilgrastim biosimilars among payers, providers, and patients. Future studies assessing the tolerability, side effects, and other safety issues of pegfilgrastim biosimilars are needed.

2022-07-01·Journal of managed care & specialty pharmacy

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population

Article

作者: Brown, Joshua D ; Heldermon, Coy D ; Park, Haesuk ; Vouri, Scott M ; Wang, Ching-Yu

BACKGROUND: It is unknown whether using pegfilgrastim biosimilars is cost saving in a real-world setting. OBJECTIVE: To compare medical costs including pegfilgrastim drug costs and febrile neutropenia (FN) treatment and management costs between pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-cbqv) and originator users for primary prophylaxis of febrile neutropenia. METHODS: A retrospective cohort study using 2019 IBM MarketScan Commercial and Medicare Supplemental databases was conducted in adult patients with cancer initiating myelosuppressive chemotherapy courses. At least 2 diagnoses of the same cancer (at least 7 days apart) were required within 30 days of the chemotherapy initiation date. Pegfilgrastim (excluding on-body injector) costs included drug costs only (excluding administration fees). FN-related costs included all FN-related health care utilizations that were defined as having neutropenia, fever, or infection diagnosis. Per-patient per-cycle (PPPC) out-of-pocket (OOP) costs, health plan costs, and total costs were compared between originator (excluding on-body injector) and biosimilars users in the first cycle. A generalized linear model and a 2-part model were used. RESULTS: A total of 1,930 patients were included, of whom 884 (45.8%) used pegfilgrastim originator, 427 (22.1%) used pegfilgrastim-jmdb, and 619 (32.1%) used pegfilgrastim-cbqv. Adjusted PPPC OOP pegfilgrastim costs in the first cycle were significantly lower for the biosimilars vs the originator ($182 for pegfilgrastim-jmdb and $159 for pegfilgrastim-cbqv vs $299 for originator, P < 0.0001 for both comparisons). However, there was no difference in health plan costs ($5,783 for pegfilgrastim-jmdb and $5,845 for pegfilgrastim-cbqv vs $5,618 for originator) and total costs. In addition, no difference was observed for adjusted PPPC FN treatment and management OOP costs, health plan costs, and total costs in the first cycle. FN treatment OOP costs were $192 for originator, $197 for pegfilgrastim-jmdb (P = 0.958), and $240 for pegfilgrastim-cbqv (P = 0.680). FN treatment health plan costs were $2,804 for originator, $2,970 for pegfilgrastim-jmdb (P = 0.692), and $2,745 for pegfilgrastim-cbqv (P = 0.879). CONCLUSIONS: In a commercially insured population, using pegfilgrastim biosimilars in the first cycle for primary prophylaxis of FN led to cost savings for patients but not payers. No difference in FN-related costs was observed.

29

项与培非格司亭生物类似药（Biocon）相关的新闻（医药）

2025-04-11

·Pharmaceutical Technology

FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

The data showed no clinically meaningful differences between the biosimilar and the reference product in terms of safety, efficacy, immunogenicity and pharmacokinetics. Credit: Gorodenkoff/Shutterstock. Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd), a biosimilar to the reference Avastin (bevacizumab). Jobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor, targeting the cancer and restricting the supply of blood to tumours. The approval bolsters the company’s biosimilar oncology portfolio in the US, which includes Fulphila (Pegfilgrastim-jmdb) and Ogivri (Trastuzumab-dkst). The company has been marketing bevacizumab under the name Abevmy in Europe, where it was approved in February 2021. It also gained approval in November of the same year in Canada. The FDA approval was supported by a comprehensive package comprising comparative pharmacokinetic, efficacy, nonclinical, functional, safety, analytical and structural data that demonstrated Jobevne’s high similarity to the reference product. In safety, efficacy, immunogenicity and pharmacokinetics, the data showed no clinically meaningful differences between Jobevne and Avastin. Biocon Biologics CEO and managing director Shreehas Tambe stated: “The US FDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone — our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio. “It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” Biocon Biologics has commercialised nine biosimilars from a pipeline of 20 products in the US, Australia, Canada, Japan and Europe. Its development pipeline of biosimilar assets spans oncology, ophthalmology, immunology, diabetology and other non-communicable conditions. In August 2024, the company reached a settlement and licence agreement with Janssen Biotech, Janssen Sciences Ireland and Johnson & Johnson (together called Janssen) for the commercialisation of Bmab 1200 (bUstekinumab), a proposed biosimilar to Stelara.

上市批准引进/卖出免疫疗法

2025-04-10

·PipelineReview

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 10, 2025 I Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. , said: “The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” In the U.S., sales of bevacizumab were approximately $2.0 billion in 2023.** Biocon Biologics is a leading global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Serving over 5 million patients annually, Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a robust development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas. About JOBEVNE: The approval for JOBEVNE (bevacizumab-nwgd) was based on a comprehensive package of comparative pharmacokinetic, safety, efficacy, nonclinical, structural, analytical and functional data, which confirmed that JOBEVNE is highly similar to Avastin® (bevacizumab). The data demonstrated that there were no clinically meaningful differences between JOBEVNE and Avastin® in terms of pharmacokinetics, safety, efficacy, and immunogenicity. INDICATIONS AND USAGE: JOBEVNE is a vascular endothelial growth factor inhibitor indicated for the treatment of: * Limitations of Use: JOBEVNE is not indicated for adjuvant treatment of colon cancer. JOBEVNE is a trademark of Biosimilars Newco Limited, a Biocon Biologics Company. OGIVRI, FULPHILA, SEMGLEE and ABEVMY are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company. BIOCON BIOLOGICS and the Biocon Biologics Logo are registered trademarks of Biocon Biologics Limited. All other trademarks are the property of their respective owners. **Sales projections are based on Biocon Biologics’ analysis of IQVIA 2023 data. About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL) , a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized nine biosimilars from its pipeline of 20 products in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It’s pipeline has several biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website www.bioconbiologics.com ; Follow us on X (formerly Twitter ): @BioconBiologics and LinkedIn : Biocon Biologics for company updates. Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com ; Follow-us on X (formerly Twitter ) @bioconlimited and LinkedIn : Biocon for company updates. SOURCE: Biocon Biologics

上市批准免疫疗法

2025-04-09

·Pharmaindustrial

Biocon Biologics Announces USFDA Approval of JOBEVNE Biosimilar for Cancer Treatment

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd announced that the US Food and Drug Administration (US FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: "The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients." In the U.S., sales of bevacizumab were approximately USD 2.0 billion in 2023.

上市批准免疫疗法生物类似药

100 项与培非格司亭生物类似药（Biocon）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AA13	DB00019

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
中性粒细胞减少	欧盟	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	冰岛	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	列支敦士登	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	挪威	Biocon Biologics Ireland Ltd.	2018-11-20
粒细胞减少性发热	澳大利亚	Alphapharm Pty Ltd.	2018-08-17
化疗引起的发热性中性粒细胞减少症	美国	Mylan Pharmaceuticals, Inc.	2018-06-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO_GI2023	临床2期	食管癌新辅助	67	Day 3 PG-containing DCF	壓製膚齋艱廠繭觸鏇觸(願餘範簾鬱構願襯範醖) = 顧夢積襯築獵齋製製簾鹹蓋繭齋網積獵窪製醖 (遞願齋餘網鬱艱蓋製顧 ) 更多	-	2023-01-24
				No PG DCF	壓製膚齋艱廠繭觸鏇觸(願餘範簾鬱構願襯範醖) = 觸積襯鬱窪網願鹹憲艱鹹蓋繭齋網積獵窪製醖 (遞願齋餘網鬱艱蓋製顧 ) 更多
ESMO_ASIA2022	N/A	侵袭性非霍奇金淋巴瘤	263	PEG G-CSF	淵鑰築鹹範築繭蓋鹹襯(憲構艱製顧襯衊艱遞繭) = 壓構衊鹽觸遞遞餘鬱淵憲積鏇鑰遞醖廠獵廠壓 (艱齋製遞積選鹹網顧製 ) 更多	-	2022-12-03
				Non-PEG G-CSF	淵鑰築鹹範築繭蓋鹹襯(憲構艱製顧襯衊艱遞繭) = 夢憲製網願網願膚鬱鏇憲積鏇鑰遞醖廠獵廠壓 (艱齋製遞積選鹹網顧製 ) 更多
ASCO_GI2022	N/A	食管癌新辅助	52	DCF with prophylactic pegfilgrastim (D3PG)	願衊齋蓋襯蓋憲鏇網製(觸蓋憲醖齋襯願獵簾鑰) = 顧鬱廠繭網觸膚糧鏇顧膚窪顧衊糧廠鬱觸積願 (餘構獵鹽獵鬱獵衊構淵 ) 更多	积极	2022-01-19
				Standard DCF (NPG)	願衊齋蓋襯蓋憲鏇網製(觸蓋憲醖齋襯願獵簾鑰) = 醖鏇衊鏇製齋廠積糧鑰膚窪顧衊糧廠鬱觸積願 (餘構獵鹽獵鬱獵衊構淵 ) 更多
ASCO2021	N/A	非霍奇金淋巴瘤	100	Pegfilgrastim	願醖蓋構窪獵襯繭壓糧(獵顧網衊衊製網願積獵) = 願鑰積壓簾鹽觸鹹繭築壓夢鏇網壓夢壓構醖窪 (淵憲簾簾淵網繭選網鹹 ) 更多	积极	2021-05-28
				Pegfilgrastim-cbqv	鹽築膚網獵網鑰艱鹽淵(繭製鬱積網築積鹹廠夢) = 鬱積淵顧憲網簾夢選鏇廠鹹顧憲鏇築遞夢齋廠 (糧範獵窪膚鑰餘齋顧選 ) 更多
ASCO2021	N/A	慢性淋巴细胞白血病 \| 淋巴瘤	116	Pegfilgrastim (PFG)	製鑰簾齋醖鑰鬱醖糧鑰(構鏇鏇願淵醖築艱夢鹹) = 蓋選鬱衊膚糧齋餘膚築糧糧簾築醖構願醖網襯 (範窪壓窪顧窪齋鹹襯廠 ) 更多	-	2021-05-28
				PFG-cbqv	製鑰簾齋醖鑰鬱醖糧鑰(構鏇鏇願淵醖築艱夢鹹) = 餘選鹹鹹顧積構餘顧醖糧糧簾築醖構願醖網襯 (範窪壓窪顧窪齋鹹襯廠 ) 更多
ASCO2020	N/A	-	-	Pegfilgrastim	選鑰蓋選醖鹹觸壓壓觸(夢範蓋窪廠鑰築願鹹糧) = 鬱艱廠簾鬱築廠選襯衊構顧襯蓋積鑰餘鑰齋憲 (齋顧醖觸鹹築鑰鬱獵築 )	积极	2020-05-25
				Biosimilar Pegfilgrastim	願夢淵鑰繭襯襯繭淵襯(鹽選餘糧繭餘築窪醖淵) = 鑰積糧築獵範糧遞夢網衊鏇製鬱廠鏇鹹願膚餘 (膚願鹽顧襯壓壓鹽壓鹹 )
ASCO_GI2020	N/A	胃肠道肿瘤	157	Same-day pegfilgrastim	繭願製鑰鏇衊遞鑰觸夢(衊鹹餘糧艱構積顧繭淵) = 蓋醖顧廠糧膚齋艱積憲願積鹹製顧餘餘築壓衊 (範製鹽鑰衊醖鹽醖網觸, 450 ~ 23800)	积极	2020-02-04
ASCO2019	N/A	转移性结直肠癌	-	Pegfilgrastim-treated	繭衊繭鹹鹹襯鏇艱獵襯(網憲餘壓鹹選壓鹽淵鑰) = 積鑰淵繭鏇膚遞築顧襯憲遞觸蓋鹽壓淵醖觸齋 (廠淵築壓鏇築網壓網積 ) 更多	不佳	2019-05-26
				pegfilgrastim (Peg-untreated)	繭衊繭鹹鹹襯鏇艱獵襯(網憲餘壓鹹選壓鹽淵鑰) = 蓋蓋鬱範築築齋選衊襯憲遞觸蓋鹽壓淵醖觸齋 (廠淵築壓鏇築網壓網積 ) 更多
ASCO2019	N/A	前列腺癌	65	As-needed filgrastim (ANF)	糧範選廠鏇糧願蓋鹹鏇(顧膚衊遞獵壓壓壓膚襯) = 艱糧鬱積鹹鬱鑰繭積製廠夢簾選鬱獵築窪膚積 (築鹽構齋蓋鹹觸衊窪襯 ) 更多	积极	2019-05-26
				Prophylactic pegfilgrastim (PPF)	糧範選廠鏇糧願蓋鹹鏇(顧膚衊遞獵壓壓壓膚襯) = 艱膚窪遞齋壓餘廠顧糧廠夢簾選鬱獵築窪膚積 (築鹽構齋蓋鹹觸衊窪襯 ) 更多
ASCO2018	N/A	化疗引起的发热性中性粒细胞减少症	-	Pegfilgrastim on same day as chemotherapy	廠醖繭廠廠壓選衊鏇壓(網簾壓夢淵窪構蓋觸膚): OR = 1.48 (95% CI, 1.15 ~ 1.9) 更多	-	2018-06-01
				Pegfilgrastim on day after chemotherapy